Key result
rtPA thrombolysis resolves giant atrial lead vegetation, enabling safe transvenous lead extraction.
Why the study?
There is no standard procedure for treating lead-associated infective endocarditis with large thrombotic vegetations on cardiac device leads.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
May inform individualized extraction decisions in high-risk device endocarditis; leaves open need for standardized protocols and comparative data.
CD endocarditis is a potentially lethal complication after implantation of permanent pacemakers or implantable cardioverter-defibrillators. Complete extraction of the hardware along with antibiotic treatment is the standard therapy. However, there is no standard procedure in the treatment of lead-associated infective endocarditis with large thrombotic vegetations. The authors present the case of a 60-year-old patient with a large vegetation located on the right atrial lead. Due to a high surgical and thrombembolic risk, especially of acute massive pulmonary embolism, the patient received recombinant tissue plasminogen activator to dissolve the thrombus under echocardiographic monitoring. The thrombotic masses were substantially reduced after thrombolysis. Therefore, standard transvenous extraction of the leads could be performed and high risk cardiac re-operation could be avoided.
No takes yet. Share an insight, caveat, or question.
Mueller et al. (2012) conducted a case report in Lead-associated infective endocarditis (n=1). Recombinant tissue plasminogen activator (thrombolysis) was evaluated on Reduction of thrombotic masses and successful transvenous lead extraction. Thrombolysis using recombinant tissue plasminogen activator successfully reduced a giant right atrial lead vegetation in a 60-year-old patient, enabling safe transvenous lead extraction.
Synapse has enriched 10 related papers. Consider them for comparative context: